retatrutide trial doses type 2 diabetes dosing schedule Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes Retatrutide 10 mg: vial guide

ResMed CEO: Big Pharma is squarely focused on GLP-1 medications right now Image courtesy of ResMed ResMed CEO Mick Farrells stance on the issue is that the latest advances in both Big Tech and Big Pharma can potentially bring incredible numbers of new patients into the healthcare system where ResMed is uniquely positioned to provide ongoing care at home. Patients are voting with their wallets and respiratory therapists and physicians are voting with their recommendations and their prescriptions. During the companys first-quarter earnings call, Farrell said the company is laser-focused on growing the market to help people get on the therapy they need and on a pathway to better sleep, better health, and better long-term care

The FDA has issued warnings about products making unauthorized GLP-1 claims According to the FDA's Office of Criminal Investigations , multiple enforcement actions have been taken against companies marketing unapproved products as GLP-1 alternatives

For those taking insulin or sulfonylureas, this may increase hypoglycaemia risk, requiring medication review

& Pearson, E

It can also cause cardiac arrhythmias